Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes aim at stubborn blood sugar

NCT ID NCT00814372

Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing an experimental oral drug called MBX-102 in adults with type 2 diabetes whose blood sugar remains too high on metformin alone. The trial compares two doses of MBX-102 with a placebo and with Actos, an approved diabetes drug. About 242 participants take the study drug for up to 24 weeks while staying on metformin. The main goal is to see how much MBX-102 lowers HbA1c, a marker of average blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MBX-102, an experimental oral drug
What this could lead to
If it works, MBX-102 could offer another option for people whose blood sugar stays high on metformin alone.
What could go wrong
This is a mid-stage trial, so researchers still need to confirm any benefit in larger studies. MBX-102 may not control blood sugar better than existing drugs, and it can cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

242 people

The number who actually took part.

Start date

Dec 2008

Finished

Feb 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with type 2 diabetes who have been on metformin for the last 6 months and are taking a stable dose of metformin (≥ 1500 mg/d) as monotherapy for at least the last 3 months * Male or female, 18-70 years of age * All female patients must be surgically sterile or post-menopausal (at least 40 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two medically accepted methods of contraception including a barrier method. Depo contraceptives are excluded. * Female patients must not be pregnant or lactating * BMI ≥ 26 (patients of Asian Indian origin ≥ 22) kg/m2 * HbA1c ≥ 7.5%, ≤ 10.5% * FPG ≥ 120 mg/dL, ≤ 240 mg/dL Exclusion Criteria: * History of diabetes secondary to pancreatitis or pancreatectomy * Any history of ketoacidosis * History of insulin use within last one year (insulin use while hospitalized is acceptable) * Weight loss \> 10 pounds in the three months prior to screening visit * History of TZD use (Actos® or Avandia®) within 6 months of screening visit * History of TZD discontinuation due to side effect or lack of efficacy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • All India Institute of Medical Sciences

    New Delhi, India

  • American Institute of Research

    Los Angeles, California, 90017, United States

  • Amrita Institute of Medical Sciences

    Kochi, India

  • BYL Nair Hospital

    Mumbai, India

  • Bangalore Diabetes Centre

    Bangalore, India

  • Bharti Research Institute of Diabetes & Endocrinology

    Karnāl, India

  • Christian Medical College

    Vellore, India

  • DGD Research, Inc.

    San Antonio, Texas, 78229, United States

  • Deenanath Mangeshkar Hospital & Research Centre

    Pune, India

  • Diabetes Action Centre

    Mumbai, 400067, India

  • Diabetes Care & Research Centre

    Pune, India

  • Diabetes Thyroid Hormone Research Institute Pvt. Ltd.

    Indore, India

  • Diacon Hospital Diabetes & Research Centre

    Bangalore, India

  • Dr. V. Seshiah Diabetes Care & Research Institute

    Chennai, India

  • Fortis Hospital

    Jaipur, India

  • Gandhi Endocrinology & Diabetes Centre

    Nagpur, India

  • Health & Research Centre

    Trivendrum, India

  • Kamineni Hospitals Pvt, Ltd.

    Hyderabad, Andhra Pradesh, 50008, India

  • M. S. Ramaiah Memorial Hospital

    Bangalore, India

  • Mediciti Hospital

    Hyderabad, India

  • Medwin Hospital

    Hyderabad, India

  • Nevada Alliance Against Diabetes

    Las Vegas, Nevada, 89101, United States

  • PD Hindhuja National Hospital

    Mumbai, India

  • Piedmont Medical Research Associates

    Winston-Salem, North Carolina, 27103, United States

  • Providence Clinical Research

    Burbank, California, 91505, United States

  • St. John's Medical College & Hospital

    Bangalore, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.